Headshot of Tina Rydén-Bergsten, Global Product Leader, AstraZeneca

I am a medical oncologist and drug developer passionate about bringing practice-changing medicines to patients with cancer. As Vice President of Early Oncology Development at AstraZeneca, I am responsible for the strategic planning and execution of the early portfolio of oncology medicines.

I oversee a growing, global team including clinical projects, translational medicine and cancer biomarker development, and lead AstraZeneca’s diverse early-stage oncology portfolio, focused on solid tumour oncology.

I completed my medical training at Johns Hopkins University School of Medicine, Massachusetts General Hospital, and Memorial Sloan Kettering Cancer Center. In my previous role as an Attending Physician at Memorial Sloan Kettering Cancer Center, I focused on treating patients with lung cancer, developing novel immunotherapies, and identifying biomarkers for benefit to immunotherapy.

Those clinical and scientific successes were incredibly exciting and set me on the path to becoming a drug developer. I’m delighted to use that clinical grounding every day in the work we do at AstraZeneca.  


Our mission is to build the next generation of anti-cancer regimens to enable a future where we eliminate cancer as a cause of death. Our portfolio of medicines is purposefully diverse -- including antibody drug conjugates, radioconjugates, small molecules, immune-oncology agents, T cell engagers and cell therapies – in order to create orthogonal combination regimens which elicit deeper, more durable responses.

Matt Hellmann Vice President, Early Oncology Development, AstraZeneca

Headshot of Matt Hellmann, Vice President, Early Oncology Development, AstraZeneca

CURRENT ROLE

Vice President, Early Oncology Development, AstraZeneca

2023 – present

Serving as Vice President Early Oncology Development, Chair, Early Oncology Leadership Team and Co-Chair, Oncology Research Board AstraZeneca

2021 – present

Serving as Vice President, Early Oncology Clinical Group

2014 – 2021

Served as Attending Physician: Memorial Sloan Kettering Cancer Center, Thoracic Oncology Group and Early Drug Development Group

  Featured publications

Veeva ID: Z4-65546
Date of preparation: June 2024